...neues 3 Mrd. Aktienrückkaufprogramm
Aug 3 (Reuters) - Moderna Inc MRNA.O on Wednesday maintained its full-year sales outlook for its COVID-19 vaccine, following a similar prediction by bigger rival Pfizer Inc PFE.N a week ago, amid tepid demand from low-to-middle income countries.
The company expects $21 billion in vaccine sales this year. The unchanged forecast comes despite Moderna's $1.74 billion deal last week with the U.S. government for 66 million doses of a vaccine updated for Omicron subvariants.
Market expectations of an increase in vaccine sales have been dropping, with analysts divided on the sustainability of that dizzying growth beyond 2022 on doubts over demand for booster doses.
Moderna reported $4.5 billion in sales of its shot in the second-quarter ended June 30. Three analysts polled by Refinitiv had expected quarterly sales of $3.16 billion.
Last year, Pfizer had raised its vaccine sales forecast every quarter, while Moderna hiked it several times.
The vaccine maker also announced a $3 billion share buyback plan.
|